{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:27:47Z","timestamp":1782534467755,"version":"3.54.5"},"reference-count":19,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"6","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2010]]},"DOI":"10.2133\/dmpk.dmpk-09-rg-024","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T05:20:23Z","timestamp":1287120023000},"page":"551-559","source":"Crossref","is-referenced-by-count":5,"title":["A Population Approach to Eplerenone Pharmacokinetics and Saturable Protein Binding"],"prefix":"10.2133","volume":"25","author":[{"given":"Yuko","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy- spironolactone derivatives: Characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","article-title":"Recent studies with eplerenone, a novel selective aldosterone receptor antagonist","volume":"1","author":"McMahon","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1124\/dmd.30.12.1344","article-title":"Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5","volume":"30","author":"Cook","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0020","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jps.10124","article-title":"Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form","volume":"91","author":"Cook","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0025","author":"FDA"},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0030","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0035","unstructured":"US Labeling of Inspra\u2122, April 2008."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1570-0232(02)00964-9","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometric assay for eplerenone and its hydrolyzed metabolite in human plasma","volume":"787","author":"Zhang","year":"2003","journal-title":"J. Chromatogr. B"},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0045","series-title":"NON- MEM Users Guides","year":"1989"},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/138920007780866799","article-title":"Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs","volume":"8","author":"McGinnity","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF01067965","article-title":"The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: The reversible metabolism of methyl-prednisolone and methylprednisone in rabbits","volume":"14","author":"Ebling","year":"1986","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0060","first-page":"143","article-title":"Clinical Pharmacokinetics-Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0065","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1023\/A:1007597713530","article-title":"Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog","volume":"17","author":"Cook","year":"2000","journal-title":"Pharm. Res."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2133\/dmpk.17.292","article-title":"Nonlinear pharmacokinetics of aprindine in guinea pigs","volume":"17","author":"Shimizu","year":"2002","journal-title":"Drug Metabol. Pharmacokin."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/cpt1974153261","article-title":"Nonlinear plasma level response to high doses of naproxen","volume":"15","author":"Rukel","year":"1973","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt1976203269","article-title":"Pharmacokinetics of naproxen overdoses","volume":"20","author":"Runkel","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/009127009603601102","article-title":"Inverse nonlinear pharmacokinetics of total and pro- tein unbound drug (oxaprozin): Clinical and pharmacokinetic implications","volume":"36","author":"Karim","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0090","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-003-0602-3","article-title":"Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia","volume":"51","author":"Petersen","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-09-RG-024_bb0095","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10928-007-9050-8","article-title":"A Pharmacokinetic\/pharmacodynamic approach to predict total prednisolone concentrations in human plasma","volume":"34","author":"Xu","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715300689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715300689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T20:10:35Z","timestamp":1740600635000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715300689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"alternative-id":["S1347436715300689"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-09-rg-024","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}